目的 分析來(lái)氟米特片聯(lián)合腎易通顆粒治療系膜增生性腎小球腎炎的臨床效果。方法 采用病例對(duì)照分析研究，將65例患者隨機(jī)分為來(lái)氟米特組（25例）、來(lái)氟米特加腎易通組（20例）、腎易通組（20例）。觀察臨床癥狀、體征以及尿常規(guī)、尿紅細(xì)胞計(jì)數(shù)、24 h尿蛋白定量、血清白蛋白（ALB）、血常規(guī)、血尿素氮、血肌酐（Ser）、谷丙轉(zhuǎn)氨酶、谷草轉(zhuǎn)氨酶的變化以及用藥期間不良反應(yīng)。結(jié)果 來(lái)氟米特組各療程有效率雖較腎易通組高，但差異無(wú)顯著性（P＞0.05）；來(lái)氟米特加腎易通組治療6個(gè)月后的療效（100%）不僅優(yōu)于腎易通組（P＜0.05），而且優(yōu)于來(lái)氟米特組（P＜0.05）。結(jié)論 來(lái)氟米特聯(lián)合腎易通顆粒對(duì)系膜增生性腎小球腎炎患者具有療效好、不良反應(yīng)少的特點(diǎn)，值得臨床推廣。

Objective To observe the clinical efficacy of leflunomide and Shenyitong Granule combination in treatment of mesangial proliferative glomerulonephritis. Methods Sixty-five patients were randomly divided into the leflunomide group (25 cases), leflunomide plus Shenyitong Granule group (20 cases), and Shenyitong Granule group (20 cases). Clinical symptoms, signs, urine, 24 h urinary protein excretion, serum albumin (ALB), urinary red blood cell count, blood count, blood urea nitrogen, serum creatinine (Ser), alanine aminotransferase, and aspartate aminotransferase were tested as well as the adverse reactions were observed during the treatment. Results There were no significant difference between leflunomide group and Shenyitong Granule group (P>0.05). Six months later, the efficacy of leflunomide plus Shenyitong Granule group (100%) was better than Shenyitong Granule group (P<0.05) and the leflunomide group (P<0.05). Conclusion In combination of leflunomide and Shenyitong Granule are effective in treatment of mesangial proliferative glomerulonephriti with little adverse reaction and fewer side effects, which is worth of spreading in clinic.